Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.
|
34. An automatic injection device, comprising:
a housing enclosing a cavity for accommodating a container, the housing comprising:
a first overmolded gripping region,
a second overmolded gripping region, and
a recessed region between and in contact with both the first and second overmolded gripping regions.
1. An automatic injection device, comprising:
a housing enclosing a cavity for accommodating a container, a proximal portion of the housing having a tapered tubular structure with a substantially oval cross-section;
a first overmolded gripping surface extending longitudinally along a portion of the housing on a first exterior surface of the housing;
a second overmolded gripping surface extending longitudinally along a portion of the housing on a second exterior surface of the housing, the first exterior surface and the second exterior surface located on opposing sides of the housing;
a first concave portion disposed in the first exterior surface of the housing between the first overmolded gripping surface and a proximal terminal end of the housing; and
a second concave portion disposed in the second exterior surface of the housing between the second overmolded gripping surface and the proximal terminal end of the housing.
22. A method for assembling an automatic injection device, the method comprising:
providing a housing enclosing a cavity for accommodating a container, a proximal portion of the housing having a tapered tubular structure with a substantially oval cross-section;
overmolding, on the housing, a first gripping surface extending longitudinally along a portion of the housing on a first exterior surface of the housing;
overmolding, on the housing, a second gripping surface extending longitudinally along a portion of the housing on a second exterior surface of the housing opposite to the first exterior surface;
providing a first concave portion disposed in the first exterior surface of the housing between the first overmolded gripping surface and a proximal terminal end of the housing; and
providing a second concave portion disposed in the second exterior surface of the housing between the second overmolded gripping surface and the proximal terminal end of the housing.
2. The automatic injection device of
3. The automatic injection device of
4. The automatic injection device of
5. The automatic injection device of
6. The automatic injection device of
a removable distal cap for protectively covering an injection needle couplable to the container, an exterior surface of the distal cap including an overmolded gripping surface for facilitating gripping and removal of the distal cap.
7. The automatic injection device of
8. The automatic injection device of
a firing button protruding from an aperture in the housing and including an overmolded contact surface for facilitating actuation of the firing button by a user.
9. The automatic injection device of
10. The automatic injection device of
a recessed surface provided adjacent to the firing button.
11. The automatic injection device of
12. The automatic injection device of
a proximal terminal end for covering a proximal end of the automatic injection device, the proximal terminal end having an overmolded exterior surface.
13. The automatic injection device of
14. The automatic injection device of
a transparent inspection window disposed in the housing to allow inspection of the contents of the container.
15. The automatic injection device of
16. The automatic injection device of
17. The automatic injection device of
18. The automatic injection device of
19. The automatic injection device of
21. The automatic injection device of
23. The method of
24. The method of
25. The method of
26. The method of
overmolding a gripping surface on an exterior surface of a distal cap to facilitate gripping and removal of the distal cap; and
coupling the distal cap to a distal end of the housing for protectively covering an injection needle.
27. The method of
28. The method of
overmolding a gripping surface on a firing button to facilitate activation of the firing button; and
providing the firing button within the cavity so that part of the firing button protrudes from an aperture in the housing.
29. The method of
30. The method of
forming a recessed surface abutting the firing button.
32. The method of
overmolding a gripping surface on an exterior surface of a proximal terminal end; and
coupling the proximal terminal end to a proximal end of the housing.
33. The method of
35. The automatic injection device of
36. The automatic injection device of
37. The automatic injection device of
38. The automatic injection device of
|
This application is a non-provisional of and claims priority to U.S. Provisional Patent Application No. 61/435,465, filed Jan. 24, 2011, the entire contents of which are expressly incorporated herein by reference in their entirety.
Automatic injection devices offer an alternative to manually-operated syringes for administering therapeutic agents into patients' bodies and allowing patients to self-administer therapeutic agents. Automatic injection devices may be used to administer medications under emergency conditions, for example, to administer epinephrine to counteract the effects of a severe allergic reaction. Automatic injection devices have also been described for use in administering anti-arrhythmic medications and selective thrombolytic agents during a heart attack. See, for example, U.S. Pat. Nos. 3,910,260; 4,004,577; 4,689,042; 4,755,169; and 4,795,433, the entire contents of which are incorporated herein in their entirety by reference. Various types of automatic injection devices are also described in, for example, U.S. Pat. Nos. 3,941,130; 4,261,358; 5,085,642; 5,092,843; 5,102,393; 5,267,963; 6,149,626; 6,270,479; and 6,371,939; and International Patent Publication No. WO/2008/005315, the entire contents of which are incorporated herein in their entirety by reference.
Conventionally, an automatic injection device houses a syringe and, when operated, causes the syringe to move forwardly and a needle to project from the housing so that a therapeutic agent contained in the syringe is ejected into a patient's body.
Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a left side of the housing and an overmolded right gripping surface may extend along a right side of the housing opposite to the left side.
In accordance with an exemplary embodiment, an automatic injection device is provided with a housing enclosing a cavity for accommodating a container. A first overmolded gripping surface is provided to extend longitudinally along a portion of the housing on a first exterior surface of the housing. A second overmolded griping surface is provided to extend longitudinally along a portion of the housing on a second exterior surface of the housing opposite to the first exterior surface.
In an exemplary embodiment, the first and second overmolded gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception. In an exemplary embodiment, the first and second overmolded gripping surfaces on the housing are formed of a first material having a first hardness, and non-gripping surfaces on the housing are formed of a second material having a second higher hardness.
In an exemplary embodiment, the automatic injection device includes a removable distal cap for protectively covering an injection needle couplable to the container, an exterior surface of the distal cap including an overmolded gripping surface for facilitating gripping and removal of the distal cap. In an exemplary embodiment, the automatic injection device includes a firing button protruding from an aperture in the housing and including an overmolded contact surface for facilitating actuation of the firing button by a user. In an exemplary embodiment, the automatic injection device includes a proximal terminal end for covering a proximal end of the automatic injection device, the proximal terminal end having an overmolded exterior surface. In an exemplary embodiment, a top surface of the proximal terminal end includes a recessed surface for directing and facilitating accommodation of a user's hand or finger for gripping the automatic injection device.
In accordance with another exemplary embodiment, a method is provided for assembling an automatic injection device. The method includes providing a housing enclosing a cavity for accommodating a container. The method includes overmolding, on the housing, a first gripping surface extending longitudinally along a portion of the housing on a first exterior surface of the housing. The method also includes overmolding, on the housing, a second gripping surface extending longitudinally along a portion of the housing on a second exterior surface of the housing opposite to the first exterior surface.
In an exemplary embodiment, the first and second gripping surfaces on the housing are formed of a first material having a first touch perception, and non-gripping surfaces on the housing are formed of a second material having a second touch perception. In an exemplary embodiment, the first and second gripping surfaces on the housing are formed of a first material having a first hardness, and non-gripping surfaces on the housing are formed of a second material having a second higher hardness.
In an exemplary embodiment, the method includes overmolding a gripping surface on an exterior surface of a distal cap to facilitate gripping and removal of the distal cap, and coupling the distal cap to a distal end of the housing for protectively covering an injection needle. In an exemplary embodiment, the method includes overmolding a gripping surface on a firing button to facilitate activation of the firing button, and providing the firing button within the cavity so that part of the firing button protrudes from an aperture in the housing.
In an exemplary embodiment, the method includes overmolding a gripping surface on an exterior surface of a proximal terminal end, and coupling the proximal terminal end to a proximal end of the housing. In an exemplary embodiment, a top surface of the proximal terminal end includes a recessed surface for directing a user's hand or finger for gripping the automatic injection device.
In accordance with another exemplary embodiment, an automatic injection device is provided including a housing enclosing a cavity for accommodating a container. The housing includes a first overmolded gripping region, a second overmolded gripping region, and a recessed region abutting the first and second overmolded gripping regions.
In an exemplary embodiment, the recessed region is disposed between the first and second overmolded gripping regions. In an exemplary embodiment, a width of the housing at the recessed region is smaller than a width of the housing at the first overmolded gripping region and a width of the housing at the second overmolded gripping region. In an exemplary embodiment, the recessed region lacks a gripping surface.
In an exemplary embodiment, the first overmolded gripping region is formed by a proximal terminal end of the housing having an exterior surface that is overmolded with a gripping surface. In an exemplary embodiment, the second overmolded gripping region of the housing has a tapered tubular structure.
The foregoing and other objects, aspects, features, and advantages of exemplary embodiments will become more apparent and may be better understood by referring to the following description taken in conjunction with the accompanying drawings, in which:
Exemplary embodiments provide automatic injection devices having housings that are particularly designed and configured for reliable, safe, ergonomic and comfortable handling by users. Exemplary embodiments also provide housing components for automatic injection devices that are particularly designed and configured for reliable, safe, ergonomic and comfortable handling by users. Exemplary embodiments also provide methods for fabricating exemplary housings for automatic injection devices and automatic injection devices including exemplary housings.
In one exemplary embodiment, one or more overmolded gripping surfaces may be provided on an exterior surface of an exemplary automatic injection device housing in order to allow the device to be easily, comfortably and reliably gripped and manipulated by a user. The exemplary overmolded gripping surfaces are particularly configured and positioned on the housing to prevent slippage from the hands of the user, and thereby to avoid injury to the user and others in the vicinity. Furthermore, the exemplary overmolded gripping surfaces are particularly configured and positioned to be ergonomic and comfortable to use, particularly by physically weak users, for example, older users, users who suffer from rheumatoid arthritis, and the like.
In user tests performed using exemplary automatic injection devices, test participants appreciated exemplary overmolded gripping surfaces on the sides of the devices and the relatively large size and ergonomic shape of the device. The test participants provided high ratings for handling and grip of exemplary devices, in which the overmolded gripping surfaces were the primary factor in test participants' high ratings of exemplary device configurations for handling and grip, compared to devices without overmolded gripping surfaces. For several usability factors, there was a significant positive correlation between Cochin scores and exemplary device configurations, which indicates that exemplary devices are well-suited for use by users with hand dysfunction.
An exemplary automatic injections device may contain and may be used to administer a dose of a TNFα inhibitor. In an exemplary embodiment, the TNFα inhibitor may be a human TNFα antibody or antigen-biding portion thereof. In an exemplary embodiment, the human TNFα antibody or antigen-binding portion thereof may be adalimumab (HUMIRA®) or golimumab.
Certain terms are defined in this section to facilitate understanding of exemplary embodiments.
The terms “automatic injection device” and “autoinjector,” as used herein, refer to a device that enables a patient to self-administer a therapeutically effective dose of a therapeutic agent, wherein the device differs from a conventional syringe by the inclusion of a mechanism for automatically delivering the therapeutic agent to the patient by injection when the mechanism is engaged.
The terms “vessel” and “container,” as used herein, refer to a syringe or cartridge that may be used in an exemplary automatic injection device for holding a dose of a therapeutic agent.
The terms “syringe” and “cartridge,” as used herein, refer to a sterile barrel portion of an automatic injection device that is filled with a dose of a therapeutic agent prior to distribution or sale of the device to a patient or other non-medical professional for administration of the therapeutic agent to a patient. In an exemplary embodiment, a distal end of the barrel portion of a syringe may be coupled to a sterile hypodermic injection needle. In an exemplary embodiment, a distal end of the barrel portion of a cartridge may not be coupled to an injection needle. That is, in exemplary embodiments, a syringe may be a cartridge with a pre-attached injection needle coupled to its barrel portion.
Exemplary embodiments described herein with reference to a syringe assembly may also be implemented using a cartridge assembly. Similarly, exemplary embodiments described herein with reference to a cartridge assembly may also be implemented using a syringe assembly.
The term “pre-filled syringe,” as used herein, refers to a syringe that is filled with a therapeutic agent immediately prior to administration of the therapeutic agent to a patient, and a syringe that is filled with a therapeutic agent and stored in this pre-filled form for a period of time before administration of the therapeutic agent to a patient.
The terms “injection needle” and “needle,” as used herein, refer to a needle in an automatic injection device that is inserted into a patient's body to deliver a dose of a therapeutic agent into the patient's body. In an exemplary embodiment, the injection needle may be directly coupled to or may otherwise be in contact with a syringe assembly or a cartridge assembly that holds a dose of the therapeutic agent. In another exemplary embodiment, the injection needle may be indirectly coupled to the syringe or cartridge assembly, for example, via a syringe needle and/or a transfer mechanism that provides fluid communication between the syringe or cartridge assembly and the injection needle.
The term “pre-injection state,” as used herein, refers to a state of an automatic injection device prior to activation of the device, i.e., prior to the start of delivery of a therapeutic agent contained in the device.
The term “injection state,” as used herein, refers to one or more states of an automatic injection device during the delivery of a therapeutic agent contained in the device.
The term “post-injection state,” as used herein, refers to completion of delivery of a therapeutically effective dose of a therapeutic agent contained in the device, or removal of the device from the patient prior to completion of delivery of a therapeutically effective dose of the therapeutic agent.
An automatic injection device provided in accordance with exemplary embodiments may include a “therapeutically effective amount” or a “prophylactically effective amount” of an antibody or antibody portion of the invention. A “therapeutically effective amount,” as used herein, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody, antibody portion, or other TNFα inhibitor may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody, antibody portion, or other TNFα inhibitor to elicit a desired response in the patient. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody, antibody portion, or other TNFα inhibitor are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount,” as used herein, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in patients prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
The terms “substance” and “therapeutic agent,” as used herein, refer to any type of drug, biologically active agent, biological substance, chemical substance or biochemical substance that is capable of being administered in a therapeutically effective amount to a patient employing exemplary automatic injection devices. Exemplary therapeutic agents usable in exemplary automatic injection devices may include, but are not limited to, agents in a liquid state. Such agents may include, but are not limited to, adalimumab (HUMIRA®) and proteins that are in a liquid solution, e.g., fusion proteins and enzymes. Examples of proteins in solution include, but are not limited to, Pulmozyme (Dornase alfa), Regranex (Becaplermin), Activase (Alteplase), Aldurazyme (Laronidase), Amevive (Alefacept), Aranesp (Darbepoetin alfa), Becaplermin Concentrate, Betaseron (Interferon beta-1b), BOTOX (Botulinum Toxin Type A), Elitek (Rasburicase), Elspar (Asparaginase), Epogen (Epoetin alfa), Enbrel (Etanercept), Fabrazyme (Agalsidase beta), Infergen (Interferon alfacon-1), Intron A (Interferon alfa-2a), Kineret (Anakinra), MYOBLOC (Botulinum Toxin Type B), Neulasta (Pegfilgrastim), Neumega (Oprelvekin), Neupogen (Filgrastim), Ontak (Denileukin diftitox), PEGASYS (Peginterferon alfa-2a), Proleukin (Aldesleukin), Pulmozyme (Dornase alfa), Rebif (Interferon beta-1a), Regranex (Becaplermin), Retavase (Reteplase), Roferon-A (Interferon alfa-2), TNKase (Tenecteplase), and Xigris (Drotrecogin alfa), Arcalyst (Rilonacept), NPlate (Romiplostim), Mircera (methoxypolyethylene glycol-epoetin beta), Cinryze (C1 esterase inhibitor), Elaprase (idursulfase), Myozyme (alglucosidase alfa), Orencia (abatacept), Naglazyme (galsulfase), Kepivance (palifermin) and Actimmune (interferon gamma-1b).
The term “dose” or “dosage,” as used herein, refers to an amount of a therapeutic agent, such as a TNFα inhibitor, which is administered to a patient preferably using the wearable automatic injection device of the invention. In one embodiment, the dose comprises an effective amount, for example, including, but not limited to, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, and 160 mg, of the TNFα inhibitor adalimumab.
The term “dosing,” as used herein, refers to the administration of a therapeutic agent (e.g., an anti-TNFα antibody) to achieve a therapeutic objective (e.g., treatment of rheumatoid arthritis).
The term “dosing regimen,” as used herein, refers to a treatment schedule for a therapeutic agent, such as a TNFα inhibitor, e.g., a treatment schedule over a prolonged period of time and/or throughout the course of treatment, e.g. administering a first dose of a TNFα inhibitor at week 0 followed by a second dose of a TNFα inhibitor on a biweekly dosing regimen.
The term “treatment,” as used herein, refers to therapeutic treatment, as well as prophylactic or suppressive measures, for the treatment of a disorder, such as a disorder in which TNFα is detrimental, e.g., rheumatoid arthritis.
The term “patient” or “user,” as used herein, refers to any type of animal, human or non-human, that may be administered a therapeutic agent using exemplary automatic injection devices.
The term “proximal” refers to a portion or end or component of an exemplary automatic injection device that is farthest from an injection site on a patient's body when the device is held against the patient for an injection or for mimicking an injection.
The term “distal” refers to a portion or end or component of an exemplary automatic injection device that is closest to an injection site on a patient's body when the device is held against the patient for an injection or for mimicking an injection.
The term “planar” is used herein, in a broad lay sense, to mean exactly planar or approximately planar within some tolerance from the exactly planar.
The term “concave” is used herein, in a broad lay sense, to mean exactly concave or approximately concave within some tolerance from the exactly concave.
The term “convex” is used herein, in a broad lay sense, to mean exactly convex or approximately convex within some tolerance from the exactly convex.
The term “elliptical” is used herein, in a broad lay sense, to mean exactly elliptical or approximately elliptical within some tolerance from the exactly elliptical.
The term “oval” is used herein, in a broad lay sense, to mean exactly oval or approximately oval within some tolerance from the exactly oval.
The term “rectangular” is used herein, in a broad lay sense, to mean exactly rectangular or approximately rectangular within some tolerance from the exactly rectangular.
The term “parallel” is used herein, in a broad lay sense, to mean exactly parallel or approximately parallel within some tolerance from the exactly parallel.
The term “straight” is used herein, in a broad lay sense, to mean exactly straight or approximately straight within some tolerance from the exactly straight.
The term “equal” is used herein, in a broad lay sense, to mean exactly equal or approximately equal within some tolerance.
The term “adjacent” is used herein, in a broad lay sense, to mean immediately adjacent or approximately adjacent within some tolerance.
The term “abut” is used herein, in a broad lay sense, to mean immediately abutting or approximately abutting within some tolerance.
The term “transverse axis” is used herein to refer to an axis that is substantially perpendicular to a longitudinal axis.
Exemplary embodiments are described below with reference to certain illustrative embodiments. While exemplary embodiments are described with respect to using an automatic injection device to provide an injection of a dose of a therapeutic agent, one of ordinary skill in the art will recognize that exemplary embodiments are not limited to the illustrative embodiments and that exemplary automatic injection devices may be used to inject any suitable therapeutic agent into a patient. In addition, components of exemplary automatic injection devices and methods of making and using exemplary automatic injection devices are not limited to the illustrative embodiments described below.
In some exemplary embodiments, an exemplary length of the device 100 may be about 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.5, 8, 8.5, 9, 9.5, 10 inches, but is not limited to these exemplary lengths. In some exemplary embodiments, an exemplary width of the device 100 (at its widest location) may be about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 inches, but is not limited to these exemplary widths. In some exemplary embodiments, an exemplary thickness of the device 100 (at its thickest location) may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 inches, but is not limited to these exemplary thicknesses. In an exemplary embodiment, the device 100 may have an exemplary length of about 6.69 inches, an exemplary width of about 1.46 inches at the widest portion, and an exemplary thickness of about 1.15 inches at the thickest portion. In another exemplary embodiment, the device 100 may have an exemplary length of about 4.8 inches, an exemplary width of about 0.8 inches at the widest portion, and an exemplary thickness of about 0.6 inches at the thickest portion. The exemplary dimensions of the recited exemplary devices allow the device to be conformably and ergonomically held in the grip of a user's hand. This allows a user to reliably and comfortably grip and manipulate the device in order to perform an injection.
Exemplary automatic injection device 100 may include an outer housing 101 for housing a container, such as a syringe or cartridge. The container may be pre-filled with a dose of a therapeutic agent to be injected into a patient's body. The housing 101 of the device, in its assembled form, may have any suitable size and shape for storing and dispensing the dose of the therapeutic agent. The assembled housing 101 may have a shape that is designed and configured to be conformable to a user's hand and so that the user can comfortably and reliably hold the device 100 during an injection. In an exemplary embodiment, the assembled housing 101 may have an elongated structure so that its length taken along the longitudinal axis L is much greater than its width taken along the first transverse axis H and its thickness taken along a second transverse axis V. An exemplary ratio of the length to the width (at the widest location) of the device may be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like. An exemplary ratio of the length to the thickness (at the thickest location) of the device may be, but is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like.
The housing 101 of the device 100 may be formed of a plurality of body components that are assembled together. In an exemplary embodiment, the housing 101 may be formed from a first body portion 116 and a second body portion 118 that, when cooperatively engaged to each other along their peripheral edges, enclose and provide a cavity therebetween. The first and second body portions may be cooperatively engaged to each other using any suitable technique including, but not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit, screws, attachment between corresponding protrusions and recesses, and the like. One of ordinary skill in the art will recognize that, in other exemplary embodiments, the cavity of the device may be enclosed in a single body component or in three or more body components when assembled together.
A firing button 120 may extend from a surface of the first body portion 116. The firing button 120, when activated by a user, may cause an injection to be performed by the device 100. In an exemplary embodiment, a recessed or concave portion 126 may be provided on the first body portion 116 abutting the firing button 120 to facilitate activation of the firing button 120. The recessed portion 126 may surround the firing button 120 in an exemplary embodiment to accommodate a user's finger as the user presses on the firing button 120.
A transparent inspection window 128 may be provided in a surface of the first body portion 116 to allow a user to view the contents of the device 100. The transparent inspection window 128 may allow the user to view a therapeutic agent contained in the device 100, for example, to ensure clarity of the agent, and to view an end-of-injection indicator that materializes at the end of a successful injection. An exemplary inspection window 128 may be substantially elongated in shape, for example, an elongated rectangle (with sharp or rounded edges), an elongated elliptical shape, and the like, although other shapes are possible. In the elongated inspection window 128, the length extending along the longitudinal axis L may be substantially greater than the width extending along the first transverse axis H. In exemplary embodiments, a ratio between the length and the width of the inspection window may include, but is not limited to, 1.5:1, 2.0:1, 2.5:1, 3.0:1, 3.5:1, 4.0:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A proximal terminal end 172 of the device housing may be provided to cover the proximal end of the device 100. In an exemplary embodiment, the proximal terminal end 172 may be coupled to the proximal end of the assembled first and second body portions. The proximal terminal end 172 may take any suitable size and shape. In an exemplary embodiment, the proximal terminal end 172 may have a substantially tubular configuration with a substantially oval or elliptical shape. In an exemplary embodiment, at least part of the exterior surface of the proximal terminal end 172 may be overmolded with one or more gripping surfaces 173 to facilitate gripping of the proximal portion of the device. In an exemplary embodiment, the entire exterior surface of the proximal terminal end 172 may be covered by an overmolded gripping surface 173. Corresponding recesses may be provided on the exterior surface of the proximal terminal end 172 to accommodate the gripping surfaces.
A removable distal cap 164 may be coupled to the distal end of the assembled first and second body portions to cover the distal end of the device 100 in order to prevent exposure of the injection needle prior to an injection. The distal cap 164 protects against accidental and/or unwanted contact of a user with the injection needle. The distal cap 164 also protects against damage to and contamination of the injection needle when the device is not in use. The distal cap 164 may take any suitable size and shape. In an exemplary embodiment, the distal cap 164 may have a substantially tubular configuration with a substantially oval or elliptical shape. In an exemplary embodiment, a front surface of the distal cap 164 may have a concave cutout portion 168 for accommodating part of the inspection window 128.
In an exemplary embodiment, the exterior surface of the distal cap 164 may lack overmolded gripping surfaces. In other exemplary embodiments, the exterior surface of the distal cap 164 may be overmolded with one or more gripping surfaces 165 for facilitating gripping and removal of the distal cap 164 from the device. In an exemplary embodiment, the entire exterior surface of the distal cap 164 may be covered by an overmolded gripping surface 165. Corresponding recesses may be provided on the exterior surface of the distal cap 164 to accommodate the gripping surfaces.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface) and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided at the gripping surfaces 165 on the distal cap 164 to further facilitate gripping and manipulation of the device. The shapes and locations of the ridges and/or grooves may be altered as desired, and any desired number of ridges and/or grooves may be provided. In an exemplary embodiment, the ridges and/or grooves may extend substantially perpendicularly to the longitudinal axis L of the device. In an exemplary embodiment, the gripping surfaces 165 may include textured surfaces to improve the tactile feel and further facilitate firm gripping of the device. In an exemplary embodiment, the distal cap 164 may include one or more protrusions 170a, 170b (shown in
In an exemplary embodiment, the distal cap 164 may frictionally engage a recessed or stepped portion of the housing in order to be retained in position on the housing when the device is not in use. In an exemplary embodiment, the distal cap 164 may include a boss for locking and/or joining the cap to the housing until the user is ready to perform an injection. Any suitable mating mechanism may be used in accordance with the teachings of exemplary embodiments.
When the proximal terminal end 172, the first body portion 116 and the second body portion 118 are assembled together, they form a tapered tubular structure. Side surfaces of the body portions 116, 118 abutting the gripping surfaces 173 on the proximal terminal end 172 may include one or more recessed or concave portions 122, 124. In an exemplary embodiment, two recessed portions 122, 124 may be provided at opposite sides of the device abutting the firing button 120. The recessed portions allow the hand of the user to be accommodated in a comfortable position when pressing the firing button 120.
A portion of the body portions 116, 118 abutting the recessed portions 122, 124 may be overmolded with one or more gripping surfaces 154, 156 to facilitate holding and manipulation of the device. In an exemplary embodiment, two gripping surfaces 154, 156 may be provided at opposite side surfaces of the device. A first gripping surface 154 may abut a first recessed portion 122, and a second gripping surfaces 156 may abut a second recessed portion 124. Corresponding recesses may be provided on the exterior surface of the first body portion 116 to accommodate the gripping surfaces.
In an exemplary housing for an automatic injection device, a first overmolded gripping region, a second overmolded gripping region and a recessed region abutting the first and second overmolded gripping regions may be provided. The first overmolded gripping region, the second overmolded gripping region and the recessed region may cooperatively provide an ergonomic and comfortable gripping area at which a user may grip the automatic injection device in order to perform an injection.
In this exemplary embodiment, the first overmolded gripping region may be formed by the proximal terminal end 172 having an overmolded outer surface or covering. The second overmolded gripping region may be formed part of the assembly of the first body portion 116 and the second body portion 118 having one or more overmolded gripping surfaces (for example, gripping surfaces 154, 156). In an exemplary embodiment, the second overmolded gripping region may have a substantially tapered tubular structure for providing an ergonomic fit with a user's hand. The recessed region abutting the first and second overmolded gripping regions may be formed by a portion of the assembly of the first body portion 116 and the second body portion 118 that is narrower in width than the first overmolded gripping region and the second overmolded gripping region. In an exemplary embodiment, the recessed region may be provided between the first and second overmolded gripping regions. In an exemplary embodiment, the recessed region may lack any overmolded gripping surfaces.
In an exemplary embodiment, the second body portion 118 may include a substantially planar front surface (extending substantially along the L-H plane) and left and right side surfaces (extending substantially along the L-V plane). The front surface of the second body portion 118 may contiguously and integrally transition to left and right side surfaces of the second body portion 118. The edges at which the front surface transitions to the side surfaces may be sharp, or smooth and rounded in order to maintain a streamlined shape of the device and for ergonomic handling of the device. The front and/or side surfaces of the second body portion 118 may be substantially flat or slightly convex so that the assembled housing ergonomically fits within a user's hand. The front surface may be wider at the proximal portion 106 of the device than at the distal portion 104. One of ordinary skill in the art will recognize that other exemplary shapes are possible for the second body portion 118 of the device.
As illustrated in
An exemplary container 160 is preferably slidably positioned in the cavity 102 and is coupled to an injection needle (not shown) at a distal end. The injection needle may be covered by a needle shield 162, for example, a soft needle shield and/or a rigid needle shield. A container advancement mechanism may be provided within the housing to mechanically advance the container 160 within and relative to the housing and to eject the therapeutic agent from the container 160 for performing an injection. The container advancement mechanism may include one or more actuators (e.g., one or more biasing members) that move the container from a sheathed position to a projecting position. When the device is in a pre-injection state, the container 160 may be in a sheathed position, i.e., retracted within the housing. When the device is actuated, the container advancement mechanism may advance the container 160 to a projecting position so that the injection needle projects from a distal end of the housing to allow ejection of the therapeutic agent into a patient's body. The distal end of the housing may include an aperture through which the needle may project.
The cavity 102 within the housing may also accommodate a firing engagement mechanism, for example, the firing button 120. The firing button 120, when actuated by depressing, activates the container advancement mechanism that, in turn, advances the container 160 toward the injection site, drives the injection needle into the injection site and delivers the therapeutic agent into the injection site. In an exemplary embodiment, at least a portion of the exterior surface of the firing button 120 may be overmolded with one or more rubberized gripping surfaces to facilitate pressing of the firing button by a user's finger or hand. In an exemplary embodiment, the entire exterior surface of the firing button may be covered by an overmolded gripping surface. In an exemplary embodiment, the gripping surfaces on the firing button 120 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more gripping surfaces on the firing button 120 may be green, while all other surfaces on the device may be one or more colors that are not green.
As illustrated in
As illustrated in
One of ordinary skill in the art will recognize that other shapes are possible in exemplary automatic injection device 100.
As illustrated in
In user tests performed using exemplary automatic injection devices, test participants liked the overmolded gripping surfaces on the sides of the device, the ridges on the overmolded gripping surfaces, and the relatively large size and ergonomic shape of the device. Most test participants (58%) strongly preferred the handling and grip of an example automatic injection device of the present invention. Overall, the example device configuration received a high average rating of 8.1 out of 10.0. The overmolded gripping surfaces were the primary factor in the participants' high ratings of the example device for handling and grip. For several usability factors, there was a significant positive correlation between Cochin scores and the example device of the present invention with the overmolded gripping surfaces, which indicates that the example device of the present invention is well-suited for those with hand dysfunction.
One of ordinary skill in the art will recognize that the left and right gripping surfaces may have different sizes, shapes and configurations than the exemplary sizes, shapes and configurations shown in
The overmolded gripping surfaces provided in exemplary embodiments may be formed of any suitable material that provides a first soft and high-friction touch perception to a user, as compared to the portions of the device that lack an overmolded gripping surface which provide a second hard and low-friction touch perception to a user. The difference in the sensory perceptions provides a touch affordance to a user, indicating that the device is to be gripped at regions provided with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first type of material having a soft, high-friction touch perception to a user, while the portions of the device lacking overmolded gripping surfaces may be formed of a second type of material having a harder, lower-friction touch perception to a user. In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first material with a lower hardness, while the non-gripping surfaces may be formed of a second material with a higher hardness.
For example, the non-gripping surfaces may be formed of any rigid thermoplastic material or rigid substrate suitable for use in a medical device application and suitable for providing a hard, low-friction touch perception to the user. Rigid thermoplastics can include materials such as polypropylene (PP), polyethylene (PE), polystyrene (PS), high impact polystyrene (HIPS), polycarbonate (PC), acrynitrile-butadiene-styrene (ABS), poly(ethylene terephthalate) (PET), polyamide (PA), PC/ABS blend and PPO/PS blends.
Exemplary overmolded gripping surfaces may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user. Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50 A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like.
In an exemplary embodiment, the overmolded gripping surfaces may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the left and right overmolded gripping surfaces may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
As illustrated in
Referring to
In an exemplary embodiment, a connecting side 142 extending between ends 136, 138 may connect the first longitudinal side 134 to the first horizontal side 140. In an exemplary embodiment, the first horizontal side 140 may include a beveled edge extending to the first longitudinal side 134 at an angle to both longitudinal axis L and the first transverse axis H.
In an exemplary embodiment, the first longitudinal side 134 of the left overmolded gripping surface 130 may be substantially longer than the first horizontal side 140. An exemplary ratio of the length of the first longitudinal side 134 to the length of the first horizontal side 140 may include, but is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A distal end 144 of the first longitudinal side 134 may extend toward and connect with an end 146 of a second horizontal side 148 of the left overmolded gripping surface 130. In an exemplary embodiment, a connecting side 150 extending between the ends 144, 146 may connect the first longitudinal side 134 to the second horizontal side 148. In an exemplary embodiment, the connecting side 150 may have a length greater than that of the connecting side 142. In exemplary embodiments, a ratio of the length of the connecting side 150 to the length of the connecting side 142 may include, but is not limited to, 1.5:1, 1.75:1, 2:1, 2.25:1, 2.5:1, 2.75:1, 3:1, 3.25:1, 3.5:1, 3.75:1, 4:1, all intermediate ratios, and the like, but is not limited to these exemplary ratios. The second horizontal side 148 may extend across the left side surface of the first body portion 116 substantially along the second transverse axis V, ending at the peripheral edge of the first body portion 116.
In an exemplary embodiment, the first longitudinal side 134 may be substantially longer than either the first horizontal side 140 or the second horizontal side 148. An exemplary ratio of the length of the first longitudinal side 134 to the length of either horizontal side may include, but is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, all intermediate ratios, and the like.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first type of material having a soft, high-friction touch perception, while the non-gripping surfaces are formed of a second type of material having a harder, lower-friction touch perception. Exemplary overmolded gripping surfaces 165 may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user. Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50 A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like. In an exemplary embodiment, the overmolded gripping surfaces 165 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more overmolded gripping surfaces 165 on the distal cap 164 may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
The overmolded gripping surfaces 173 may be formed of any suitable material that provides a first soft and high-friction touch perception to a user, as compared to the portions of the device that lack an overmolded gripping surface which provide a second soft and low-friction touch perception to a user. The difference in the sensory perceptions provides a touch affordance to a user, indicating that the device is to be gripped at regions provided with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces 173 may be formed of a first type of material having a soft, high-friction touch perception, while the non-gripping surfaces are formed of a second type of material having a harder, lower-friction touch perception. Exemplary overmolded gripping surfaces 173 may be formed of materials having any suitable material grade and hardness for providing a soft, high-friction touch perception to the user. Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for example, having a durometer of 50 A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG, the Dynaflex™ TPE from PolyOne, the Versaflex™ TPE from PolyOne, the Versollan™ TPE from PolyOne, the OnFlex™ TPE from Polyone, and the like. Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like. In an exemplary embodiment, the overmolded gripping surfaces 173 may be colored differently from the non-gripping surfaces to provide a visual affordance to indicate which area of the device should be gripped. For example, the one or more overmolded gripping surfaces 173 on the proximal terminal end 172 may be maroon in color while the non-gripping surfaces on the housing may be grey in color.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface) and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided on the exterior surface of the proximal terminal end 172 to further facilitate gripping of the proximal portion of the device. The shapes and locations of the ridges and/or grooves may be altered as desired, and any desired number of ridges and/or grooves may be provided. In an exemplary embodiment, the overmolded gripping surfaces 173 may include textured surfaces to improve the tactile feel and further facilitate firm gripping of the device. In an exemplary embodiment, a wrap-around groove 174 may be provided around the circumference of the proximal terminal end 172 and a concave or recessed surface 176 may be provided at the top of the proximal terminal end 172 in order to orient and guide a user's hand and fingers to the device. For example, the concave or recessed surface 176 may accommodate a finger on the surface 176 while the user is performing an injection using the device.
In some exemplary embodiments, the housing 101, the removable distal cap 164 and/or the proximal terminal end 172 of the device 100 may further include graphics, symbols and/or numbers to facilitate use of the automatic injection device. For example, the distal cap 164 may include a depiction of an arrow on an outer surface pointing towards the distal end of the device to indicate how the device should be held relative to the patient (i.e., with the distal end adjacent to the injection site). One of ordinary skill in the art will recognize that the automatic injection device may have any suitable graphics, symbols and/or numbers to facilitate patient instruction, or the automatic injection device may omit such graphics, symbols and/or numbers.
In step 902, a first body portion of the housing is provided or formed. In step 904, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the first body portion to facilitate gripping and manipulation of the device during an injection.
In step 906, a second body portion of the housing is provided or formed. In step 908, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the second body portion to facilitate gripping and manipulation of the device during an injection.
In step 910, a proximal terminal end of the housing is provided or formed. In step 912, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the proximal terminal end to facilitate gripping and manipulation of the device.
In step 914, a removable distal cap of the housing is provided or formed. In step 916, one or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the distal cap to facilitate removal of the distal cap before performing an injection.
In step 918, a firing button of the housing is provided or formed. In step 920, one or more gripping surfaces are overmolded on the exterior surface of the firing button to facilitate activation of the firing button to perform an injection.
In step 922, one or more internal components of the automatic injection device may be positioned in a cavity defined between the upper and second body portions. Exemplary device components may include, but are not limited to, a container (e.g., a syringe) pre-filled with a therapeutic agent for injecting into a patient, an injection needle coupled to a distal end of the container, a container advancement mechanism for advancing the container within and relative to the housing toward the injection site and for ejecting the therapeutic agent from the container during an injection, a firing button for activating the container advancement mechanism, and the like.
In step 924, the upper and second body portions may be cooperatively engaged to form a body assembly that encloses and holds the internal components within the cavity. In an exemplary embodiment, the body portions may be coupled at their peripheral edges. Any suitable coupling or joining may be used in step 924 including, but not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit, screws, corresponding protrusions and recesses, and the like.
In step 926, the removable distal cap may be removably coupled at a distal end of the body assembly to cover an injection needle or a needle shield that, in turn, covers the injection needle.
In step 928, the proximal terminal end may be coupled at a proximal end of the body assembly.
Any suitable fabrication technique may be used to form any of the device components including, but not limited to, injection molding. The device components may be formed of any suitable material including, but not limited to, plastics, thermoplastics, polycarbonates, metals, and the like.
It is noted that the order of the steps discussed herein may be altered as desired and that other fabrication steps/techniques are possible and are considered within the spirit and scope of the present invention.
Automatic Injection Device User Tests
Forty-four test participants were recruited to test both the exemplary automatic injection devices having overmolded gripping surfaces of the present invention and four alternate automatic injection devices without such gripping surfaces. A majority of the participants were suffering from rheumatoid arthritis (RA) at the time of the test. The participants were diagnosed with RA from 1 to 40 years ago, with an average age of diagnosis of 9 years ago. Four participants were suffering from Crohn's disease at the time of the test.
Test Procedure
Each test participant tested the different exemplary automatic injection device configurations. In particular, in an example device use phase, each test participant performed a simulated injection (i.e., an injection with clipped needles and no medicament) using the devices. After he/she performed a simulated injection, each test participant was asked a series of follow-up questions designed to assess the participant's approval of the form and function of the devices. These questions included questions on, for example, the size, shape, ease of handling, comfort of holding, overall user experience, and the like.
Device Handling and Gripping
Upon performing simulated injections using the different device configurations, test participants were asked to provide feedback and comparative ratings on handling and grip, overall ease of use, and comfort in performing the injection steps. All device configurations were rated on a scale of 1 (very negative) to 10 (very positive).
Most test participants (58%) strongly preferred the handling and grip of the example device configuration of the present invention, compared to four alternate device configurations that did not include overmolded gripping surfaces. Test participants particularly liked the rubberized overmolded grips on the side of the example device and its relatively large size, which made the example device easy and comfortable to hold. The rubberized overmolded grips were the primary factor in participants' high ratings of the example device configuration for handling and grip as taught herein.
Furthermore, a correlation analysis was performed on hand dysfunction using the Cochin hand disability scale with the ratings provided for certain usability factors: handling and gripping, ease of use, ease of starting and performing an injection, comfort of performing injection, acceptability and overall preference. For several usability factors, there was a significant positive correlation between Cochin scores and the example device configuration of the present invention, which indicates that this example device configuration is well-suited for those with hand dysfunction.
Comfort of Device Holding and Use
Upon performing simulated injections in the example device use phase, test participants were asked to rate the comfort of holding the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces. Test participants rated each device configuration on a scale from 1 (very low confidence) to 7 (very high confidence). Most test participants favored the example device configuration of the present invention for comfort in performing injection steps, with 45% rating it the highest.
Ease of Device Use and Handling
Upon initial exposure to the example device and before receiving instructions or a demonstration on use, test participants were asked about the perceived ease of use of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces. Test participants rated each device configuration on a scale from 1 (very difficult) to 7 (very easy). All of the device configurations received high ratings for their perceived ease of use.
Upon performing simulated injections in the actual device use phase, test participants were asked to rate the ease of handling each device configuration. Test participants rated each device configuration on a scale from 1 (very low confidence) to 7 (very high confidence). Furthermore, upon performing simulated injections using the device configuration in the third actual device use phase, test participants were also asked to rate the configurations on their overall ease of use on a scale of 1 (very difficult) to 10 (very easy).
Most test participants (42%) found the example device configuration of the present invention easiest to use compared to four alternate device configurations that did not include overmolded gripping surfaces. Overall, the example device configuration of the present invention received a high average rating of 7.97 out of 10.0.
Device Size
Upon performing simulated injections in the example device use phase, test participants were asked to rate the overall size of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces on a scale of 1 (very low confidence) to 7 (very high confidence). All of the device configurations generally received positive ratings for their overall shape. In general, test participants who struggled to form a tight fist preferred larger devices. The example device configuration of the present invention generally received the highest ratings.
Device Shape
Upon performing simulated injections in the actual device use phase, test participants were asked to rate the overall shape of the example device configuration of the present invention and four alternate device configurations that did not include any overmolded gripping surfaces on a scale of 1 (very low confidence) to 7 (very high confidence).
All of the device configurations generally received positive ratings for their overall size. In general, test participants who struggled to form a tight fist preferred larger devices. With respect to the example device configuration of the present invention, many participants found that the shape fit nicely in their hand.
The contents of all references, including patents and patent applications, cited throughout this application are hereby incorporated herein by reference in their entirety. The appropriate components and methods of those references may be selected for the invention and embodiments thereof. Still further, the components and methods identified in the Background section are integral to this disclosure and can be used in conjunction with or substituted for components and methods described elsewhere in the disclosure within the scope of the invention.
In describing exemplary embodiments, specific terminology is used for the sake of clarity. For purposes of description, each specific term is intended to, at least, include all technical and functional equivalents that operate in a similar manner to accomplish a similar purpose. Additionally, in some instances where a particular exemplary embodiment includes a plurality of system elements or method steps, those elements or steps may be replaced with a single element or step. Likewise, a single element or step may be replaced with a plurality of elements or steps that serve the same purpose. Further, where parameters for various properties are specified herein for exemplary embodiments, those parameters may be adjusted up or down by 1/20th, 1/10th, ⅕th, ⅓rd, ½nd, and the like, or by rounded-off approximations thereof, unless otherwise specified. Moreover, while exemplary embodiments have been shown and described with references to particular embodiments thereof, those of ordinary skill in the art will understand that various substitutions and alterations in form and details may be made therein without departing from the scope of the invention. Further still, other aspects, functions and advantages are also within the scope of the invention.
Exemplary flowcharts are provided herein for illustrative purposes and are non-limiting examples of methods. One of ordinary skill in the art will recognize that exemplary methods may include more or fewer steps than those illustrated in the exemplary flowcharts, and that the steps in the exemplary flowcharts may be performed in a different order than shown.
Julian, Joseph F., Kurth, Mark, Eiger, Aaron B., Li, Chuan, Katz, Sabrina, Callif, Adam, Stango, James C.
Patent | Priority | Assignee | Title |
10857302, | Sep 22 2011 | AbbVie Inc. | Automatic injection device |
10869966, | Feb 20 2015 | REGENERON PHARMACEUTICALS, INC | Syringe systems, piston seal systems, stopper systems, and methods of use and assembly |
11565048, | Jan 24 2011 | Abbvie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
9943649, | Sep 22 2011 | AbbVie Inc | Automatic injection device |
9981087, | Sep 22 2011 | AbbVie Inc. | Automatic injection device |
D832424, | Sep 21 2012 | AbbVie Inc. | Automatic injection device |
Patent | Priority | Assignee | Title |
2398544, | |||
2459875, | |||
2565081, | |||
2591457, | |||
2701566, | |||
2752918, | |||
2832339, | |||
2888924, | |||
2960087, | |||
3051173, | |||
3055362, | |||
3066670, | |||
3136313, | |||
3314428, | |||
3330279, | |||
3403680, | |||
3543603, | |||
3605743, | |||
3618603, | |||
3656472, | |||
3702609, | |||
3712301, | |||
3742948, | |||
3797488, | |||
3797489, | |||
3882863, | |||
3892237, | |||
3910260, | |||
3941130, | Mar 18 1975 | Sequential trigger release for injection device | |
4004577, | Jul 17 1970 | Brunswick Biomedical Corporation | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
4031893, | May 14 1976 | Survival Technology, Inc. | Hypodermic injection device having means for varying the medicament capacity thereof |
4106770, | Sep 01 1976 | Hypodermic syringe projectile | |
4178928, | Aug 10 1977 | Cordis Corporation | Self injector |
4202314, | Nov 20 1978 | Device for injection of medicinal preparations | |
4214584, | Jan 11 1978 | Device for administering medicinal preparations | |
4226235, | Jan 25 1979 | Survival Technology, Inc. | Plural injecting device |
4258713, | Jul 23 1979 | LEVINE, ROBERT A | Automatic disposable hypodermic syringe |
4261358, | Oct 01 1979 | Automatic syringe plunger | |
4275729, | Oct 29 1979 | PLAS-PAK INDUSTRIES, INC , 40 INDUSTRIAL PARK ROAD, NIANTIC, CT 06357 A CT CORP | Adjustable dosage syringe |
4394863, | Oct 23 1981 | Survival Technology, Inc.; SURVIVAL TECHNOLOGY, INC , A CORP OF DE | Automatic injector with cartridge having separate sequentially injectable medicaments |
4425120, | Apr 15 1982 | SMITH, DOLORES A | Shielded hypodermic syringe |
4437859, | Aug 03 1981 | DRS INFUSION SYSTEMS, 29 BUSINESS PARK DR , BRANFORD, CT 06405 A CORP OF CT | Hydraulic syringe drive |
4447231, | Jul 27 1981 | Duphar International Research B.V. | Automatic injection syringe |
4530695, | Dec 31 1982 | N.J. Phillips Pty. Limited | Injector |
4565543, | Oct 27 1982 | Duphar International Research B.V. | Automatic injection device |
4573976, | May 24 1984 | SMITH DOLORES A | Shielded needle |
4578064, | Dec 21 1983 | Survival Technology Inc. | Plural dosage automatic injector with improved safety |
4624660, | Nov 02 1984 | Duphar International Research B.V. | Automatic injection device |
4637403, | Apr 08 1985 | KUDD, ARTHUR R ; DAYTON, JUDSON M | Glucose medical monitoring system |
4664653, | Feb 24 1986 | Manually operated reusable injection apparatus | |
4678461, | Nov 01 1984 | MERIDAN MEDICAL TECHNOLOGIES, INC | Automatic injector with improved glass container protector |
4689042, | May 20 1985 | MERIDAN MEDICAL TECHNOLOGIES, INC | Automatic medicament ingredient mixing and injecting apparatus |
4723937, | May 20 1985 | MERIDAN MEDICAL TECHNOLOGIES, INC | Plural dosage automatic injector with a by-pass fitment |
4755169, | May 20 1985 | MERIDAN MEDICAL TECHNOLOGIES, INC | Automatic medicament ingredient mixing and injecting apparatus |
4795432, | Feb 19 1987 | Shield assembly for hypodermic injection devices | |
4795433, | Mar 06 1985 | Survival Technology, Inc. | Automatic injector for emergency treatment |
4820286, | May 15 1986 | Duphar International Research B.V. | Automatic injector |
4822340, | Oct 11 1985 | DUPHAR INTERNATIONAL RESEARCH B V , THE NETHERLANDS A CORP | Automatic injector |
4850994, | Oct 11 1985 | PHYSIONIC GESELLSCHAFT FUR MEDIZIN- UND SYSTEMTECHNIK GMBH | Hypodermic syringe |
4852768, | Mar 25 1987 | Blendax-Werke R. Schneider GmbH & Co. | Dosing syringe |
4902279, | Oct 05 1988 | Autoject Systems Inc.; AUTOJECT SYSTEMS INC , 1001 EAST MORTON PLACE, SUITE B, HEMET | Liquid medicament safety injector |
4923447, | Feb 17 1989 | Syringe assembly | |
4927416, | Dec 02 1987 | National Medical Device Corporation; NATIONAL MEDICAL DEVICE CORPORATION, VALLEY STREAM, NY, A CORP OF DE | User-protective hypodermic syringe holder |
4929237, | Nov 07 1988 | Hypodermic needle protection device | |
4955868, | Nov 19 1987 | Disposable safety medical syringe | |
4966592, | May 05 1989 | Protective sleeve for hypodermic needle | |
4994034, | Jul 11 1989 | MDC INVESTMENT HOLDINGS, INC | Retractable needle hypodermic syringe system |
5041088, | Aug 23 1988 | MERIDAN MEDICAL TECHNOLOGIES, INC | Multiple chamber automatic injector |
5042977, | May 08 1987 | BD MEDICO S A R L | Injection device which can be cocked only in the zero position |
5049133, | Jan 24 1989 | Single-use safety syringe | |
5085641, | Jul 17 1989 | MERIDAN MEDICAL TECHNOLOGIES, INC | Conveniently carried frequent use auto-injector with improved cap structure |
5085642, | Jul 17 1989 | MERIDAN MEDICAL TECHNOLOGIES, INC | Conveniently carried frequent use autoinjector |
5092842, | May 08 1987 | BD MEDICO S A R L | Injection device with a cocking element and a second setting element |
5092843, | Apr 12 1990 | MERIDAN MEDICAL TECHNOLOGIES, INC | Dispersion multichamber auto-injector |
5102393, | Jul 17 1989 | MERIDAN MEDICAL TECHNOLOGIES, INC | Autoinjector converted from intramuscular to subcutaneous mode of injection |
5104380, | Apr 18 1988 | TURNER, ROBERT C ,; HOLMAN, RURY REGINALD,; Owen Mumford Limited | Syringe with dose metering device |
5114406, | Nov 14 1986 | BD MEDICO S A R L | Injection device for injection, especially self-administered injection, of medicament, including mechanisms for nulling and for selecting dosage, especially for use with multi-dose ampules |
5114410, | Jan 18 1991 | SYRINWORLD, S L | Disposable hypodermic syringe |
5137516, | Nov 28 1989 | Glaxo Group Limited | Triggered application device for medicament to be more descriptive of the invention |
5163918, | Jul 19 1990 | RIGHI, NARDINO; ROSSI, ROBERTO | Disposable safety syringe |
5201708, | Feb 03 1992 | MEDICAL SAFETY TECHNOLOGIES, INC | Self-locking safety syringe |
5224936, | Oct 15 1992 | Automatic self-protecting hypodermic needle assembly | |
5242240, | Oct 17 1991 | MINNESOTA SCIENTIFIC, INC | Clamping device for a surgical retractor |
5244465, | Oct 19 1988 | BYK Gulden Lomberg Chemische Fabrik GmbH | Reusable injection device for distributing a preselected dose |
5259840, | Sep 03 1991 | Locking syringe | |
5263934, | Nov 28 1991 | MEDICAL PATENT LTD | Stroke limiting syringe with retractable needle |
5267963, | Aug 21 1992 | TEXAS PHARMACEUTICALS, INC | Medication injection device |
5267972, | Jul 20 1992 | Hypodermic syringe with needle guard | |
5267976, | Mar 08 1990 | BLUE STAR CORPORATION S A A CORP OF URUGUAY | Syringe with self-retracting needle |
5273544, | Jun 13 1991 | Duphar International Research B.V. | Injection device |
5295965, | Jan 07 1992 | MERIDAN MEDICAL TECHNOLOGIES, INC | Automatic injectors |
5295975, | Oct 28 1992 | Hypodermic needle safety device with sliding outer cover | |
5298024, | Dec 28 1992 | Multi-liquid medicament delivery system with reflex valves | |
5300030, | May 30 1991 | Owen Mumford Limited | Injection devices |
5318538, | Feb 03 1992 | MEDICAL SAFETY TECHNOLOGIES, INC | Self-locking safety syringe |
5320609, | Dec 07 1992 | Eli Lilly and Company | Automatic pharmaceutical dispensing syringe |
5334144, | Oct 30 1992 | Becton, Dickinson and Company | Single use disposable needleless injector |
5342308, | Dec 01 1988 | PROGRESS CONSULTANT S R L | Single-use syringe with retractable needle |
5346480, | Dec 14 1992 | Q-MED, INC | Syringe with retractable needle |
5358489, | May 27 1993 | SHIONOGI INC | Reloadable automatic or manual emergency injection system |
5376080, | Jan 30 1991 | Single use retractable needle syringe | |
5378233, | Nov 18 1992 | Habley Medical Technology Corporation | Selected dose pharmaceutical dispenser |
5383865, | Mar 15 1993 | Eli Lilly and Company | Medication dispensing device |
5391151, | Jan 15 1991 | MERIDAN MEDICAL TECHNOLOGIES, INC | Subcutaneous injector |
5425715, | Aug 05 1993 | MERIDAN MEDICAL TECHNOLOGIES, INC | Reloadable injector |
5433712, | Jun 10 1993 | Donald E., Stiles; Randall M., Brakeman | Self-sheathing hypodermic syringe |
5478316, | Feb 02 1994 | BECTON DICKINSON FRANCE, S A | Automatic self-injection device |
5480387, | Jul 24 1991 | B D MEDICO S A R L | Injection device |
5531705, | Nov 30 1990 | Nujenko Pty Ltd | Syringe unit |
5569192, | Mar 27 1992 | Duphar International Research B.V. | Automatic injector |
5591138, | Aug 10 1995 | Protected needle assembly | |
5599309, | Mar 24 1993 | Owen Mumford Limited | Injection devices |
5616128, | Jan 27 1993 | MED-Plastic AG | Self-injection device |
5620421, | Dec 09 1993 | WILLIAM LEWIS SCHMITZ TRUST OF 1989, THE, DATED FEBRUARY 24, 1989, WILLIAM LEW SCHMITZ TRUSTOR; WILLIAM LEWIS SCHMITZ TRUST OF 1989 DATED FEBRUARY | Syringe injector system |
5634906, | Dec 27 1995 | Habley Medical Technology Corporation | Needle hiding shield for a dose metering syringe |
5637094, | Nov 04 1994 | Pos-T-Vac, Inc. | Multiple dosage syringe |
5645534, | Jun 24 1994 | Becton Dickinson and Company; Becton, Dickinson and Company | Time of last injection indicator for medication delivery pen |
5658259, | Oct 19 1995 | MERIDIAN MEDICAL TECHNOLOGIES, INC | Dental cartridge assembly auto-injector with protective needle cover |
5681291, | Nov 19 1992 | Tebro S.A. | Disposable auto-injector for prefilled syringes |
5744360, | Jul 01 1994 | Edwards Lifesciences Corporation | Methods for harvesting adipose tissue containing autologous microvascular endothelial cells |
5779677, | Jan 17 1994 | Laboratoire Aguettant | Automatic drug injector |
5807335, | Dec 22 1995 | PESCADERO BEACH HOLDINGS CORPORATION | Fluid delivery device with conformable ullage and fill assembly |
5807346, | Feb 08 1993 | Laboratoire Aguettant | Metering instrument, particularly for injecting medicinal liquid |
5817111, | Mar 28 1997 | Open loop suture snare | |
5843036, | Aug 23 1996 | BECTON DICKINSON FRANCE, S A | Non-dosing cartridge for an injection device |
5885250, | Oct 11 1995 | PESCADERO BEACH HOLDINGS CORPORATION | Fluid delivery device with conformable ullage |
5931817, | Sep 12 1997 | Becton Dickinson and Company; Becton, Dickinson and Company | Pen needle assembly |
5957886, | Mar 10 1995 | ZOGENIX, INC | Spring-Powered dispensing device |
5957897, | Jun 17 1994 | Safe-T-Limited | Hollow needle applicator for cartridged drugs |
5984900, | Nov 29 1991 | Novo Nordisk A/S | Automatic pen-shaped syringe |
5993421, | Dec 02 1994 | PESCADERO BEACH HOLDINGS CORPORATION | Medicament dispenser |
6048336, | Mar 03 1997 | BD MEDICO S A R L | Injection device |
6056728, | Feb 12 1996 | Rhone- Poulenc Rorer Arzneimittel GmbH | Device for dispensing discrete doses of a liquid |
6077247, | Jun 18 1996 | Owen Mumford Limited | Injection devices |
6090070, | Feb 10 1997 | Rhone-Poulenc Rorer GmbH | Device for administering metered amounts of a liquid medicament |
6090080, | Jul 05 1996 | TecPharma Licensing AG | Injection device for injection of liquid |
6090382, | Feb 09 1996 | AbbVie Biotechnology Ltd | Human antibodies that bind human TNFα |
6099503, | Apr 18 1995 | Tebro | Reloadable auto-injector |
6102896, | Sep 08 1999 | NOVA Bio-Pharma Technologies Limited | Disposable injector device |
6110147, | Jul 12 1995 | Tech Group Europe Limited | Self-protected injection syringe |
6149626, | Oct 03 1997 | Automatic injecting syringe apparatus | |
6159181, | Apr 16 1999 | Owen Mumford Limited of Brook Hill | Injection device |
6171285, | Oct 06 1999 | Retractable syringe | |
6203530, | Jan 28 1997 | Pos-T-Vac, Inc. | Auto-injection device |
6210369, | Dec 16 1997 | MERIDIAN MEDICAL TECHNOLOGIES INC | Automatic injector |
6213987, | Aug 02 1999 | Shroud for a used hypodermic syringe needle | |
6221044, | May 02 1996 | Automatic injection device | |
6241709, | May 30 1994 | Haselmeier AG | Injection device |
6258068, | May 15 1998 | TecPharma Licensing AG | Device for administering an injectable product |
6258562, | Feb 09 1996 | AbbVie Biotechnology Ltd | Human antibodies that bind human TNFα |
6270479, | Oct 26 1998 | SHL MEDICAL AG | Autoinjector |
6277097, | Mar 25 1997 | Novo Nordisk A S | Injection system |
6277098, | Mar 12 1996 | Novo Nordisk A/S | Injection device with electronic presentation of set doses |
6277099, | Aug 06 1999 | Becton, Dickinson and Company | Medication delivery pen |
6280421, | May 15 1998 | TecPharma Licensing AG | Automatic injection device |
6312412, | Dec 02 1998 | V. C., Saied, M.D.; V C SAIED, M D | Apparatus and method for painless intramuscular or subcutaneous injections |
6319233, | Apr 17 1998 | RICHARD J RODRICK, ESQ | Safety shield system for prefilled syringes |
6319234, | Feb 09 1998 | Disposable safety syringe | |
6322540, | Mar 10 2000 | International Technology Group | Safe needle device for syringe |
6371939, | Oct 26 1998 | SHL MEDICAL AG | Autoinjector |
6387074, | Nov 13 1996 | Astra Aktiebolag | Two-chamber drug delivery device comprising a separating membrane |
6387078, | Dec 21 2000 | WEST PHARMACEUTICAL SERVICES OF DELAWARE, INC | Automatic mixing and injecting apparatus |
6413237, | Aug 31 2000 | Becton, Dickinson and Company | Hypodermic syringe with selectively retractable needle |
6419658, | Jan 20 1998 | Disposable safety syringe | |
6454746, | Jun 04 1997 | Eli Lilly and Company | Medication delivery apparatus |
6475194, | Apr 05 2000 | GEM PLASTICS, INC , DBA CREATIVE PLASTICS AND DESIGN, INC | Safety syringe |
6509015, | Feb 09 1996 | AbbVie Biotechnology Ltd | Human antibodies that bind human TNFa |
6517517, | Jun 08 2000 | Mayo Foundation for Medical Education and Research | Automated injection device for administration of liquid medicament |
6544234, | Jan 24 1998 | B D MEDICO S A R L | Injection device |
6575939, | Feb 04 1998 | Sanofi | Device for automatic injection of a dose of medicinal product |
6589210, | Feb 17 1999 | Owen Mumford Limited | Injection devices |
6656163, | Aug 21 1997 | ARES-TRADING S A | Injection devices |
6656164, | Sep 07 1999 | Computer Controlled Syringe, Inc. | Retractable needle device |
6673035, | Oct 22 1999 | FERRING INTERNATIONAL CENTER S A | Medical injector and medicament loading system for use therewith |
6692469, | Jul 31 1997 | ARES-TRADING S A | Injection devices |
6712788, | Aug 03 2001 | Automatic safety syringe | |
6743203, | Jul 27 1999 | Pharma Consult Ges.m.b.H. | Device for automatically injecting injection liquids |
6752798, | Jul 28 2000 | MDC INVESTMENT HOLDINGS, INC | Retractable needle medical device for injecting fluid from a pre-filled cartridge |
6767336, | Jan 09 2003 | Automatic injector | |
6773415, | Mar 01 2000 | Ypsomed AG | Disposable injector cap |
6796967, | Oct 22 2001 | NPS Pharmaceuticals, Inc. | Injection needle assembly |
6802827, | Jun 26 2001 | GRAY, PLANT, MOOTY, MOOTY & BENNETT, PA | Hypodermic implant device |
6805686, | May 06 2003 | AbbVie Inc | Autoinjector with extendable needle protector shroud |
6808507, | May 10 2002 | NOVA Bio-Pharma Technologies Limited | Safety injectors |
6817989, | Jun 23 2000 | Syringus AS | Needle covering mechanism, needle holder and hypodermic syringe |
6872194, | Jan 31 2002 | Safety Syringes, Inc. | Disposable self-shielding syringe guard |
6926697, | May 13 2003 | U S SAFETY SYRINGES CO , INC | Adaptor for converting a non-safety syringe into a safety syringe |
6932793, | Feb 14 1998 | Owen Mumford Limited | Medical injection devices |
6945960, | Nov 29 1999 | MDC INVESTMENT HOLDINGS, INC | Combination safety needle assembly and medical apparatus |
6976976, | Mar 27 2002 | Safety Syringes, Inc. | Syringe with needle guard injection device |
6979316, | May 23 2002 | Seedlings Life Science Ventures, LLC | Apparatus and method for rapid auto-injection of medication |
6986760, | Jul 25 2001 | Becton, Dickinson and Company | Pen needle and safety shield system |
7004929, | Mar 29 2002 | MDC Investment Holdings, Inc. | Safety pre-filled cartridge injector |
7056306, | Feb 05 1998 | MDC INVESTMENT | Fluid sampling device with retractable needle |
7223394, | Mar 16 1999 | AbbVie Biotechnology Ltd | Human antibodies that bind human TNFα |
7320682, | Nov 18 1999 | KPR U S , LLC | Safety device |
7361160, | Nov 25 2002 | TecPharma Licensing AG | Injection apparatus comprising a needle-protecting device |
7497847, | Nov 03 2003 | Becton, Dickinson and Company | Safety shield system for a syringe |
7541031, | Feb 09 1996 | AbbVie Biotechnology Ltd | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
7588761, | Feb 09 1996 | AbbVie Biotechnology Ltd | Human antibodies that bind human TNFα |
7694828, | Apr 27 2005 | Biomet, Inc; Biomet Manufacturing, LLC; ZB MANUFACTURING, LLC | Method and apparatus for producing autologous clotting components |
7736333, | Dec 21 2000 | WEST PHARMACEUTICAL SERVICES OF DELAWARE, INC | Automatic mixing and injecting apparatus |
7863426, | Apr 05 2006 | AbbVie Biotechnology Ltd | Antibody purification |
7919264, | Nov 01 2005 | AbbVie Biotechnology Ltd | Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers |
7938802, | Jun 23 2004 | AbbVie Biotechnology Ltd | Automatic injection devices |
8162887, | Jun 23 2004 | AbbVie Biotechnology Ltd | Automatic injection devices |
8372030, | Mar 31 2004 | IZI Medical Products, LLC | Apparatus for an improved high pressure medicinal dispenser |
20010005781, | |||
20010053894, | |||
20020002344, | |||
20020016563, | |||
20020042592, | |||
20020095120, | |||
20020111587, | |||
20020161337, | |||
20020169408, | |||
20020183690, | |||
20030004466, | |||
20030004467, | |||
20030023203, | |||
20030023205, | |||
20030050606, | |||
20030093036, | |||
20030105430, | |||
20030161744, | |||
20030187401, | |||
20030212362, | |||
20030229308, | |||
20030236502, | |||
20040019326, | |||
20040024367, | |||
20040025272, | |||
20040039336, | |||
20040039337, | |||
20040054319, | |||
20040054327, | |||
20040147875, | |||
20040154133, | |||
20040199117, | |||
20040215151, | |||
20040225262, | |||
20040249339, | |||
20050020979, | |||
20050020984, | |||
20050027255, | |||
20050049550, | |||
20050049561, | |||
20050085776, | |||
20050096597, | |||
20050101919, | |||
20050124940, | |||
20050137534, | |||
20050137571, | |||
20050165360, | |||
20050165361, | |||
20050165362, | |||
20050165363, | |||
20050171476, | |||
20050171477, | |||
20050209569, | |||
20050222539, | |||
20050222540, | |||
20050261634, | |||
20050273054, | |||
20050273055, | |||
20050273061, | |||
20050277885, | |||
20050277886, | |||
20050277893, | |||
20050288633, | |||
20060030819, | |||
20060036216, | |||
20060037158, | |||
20060047250, | |||
20060069350, | |||
20060069354, | |||
20060100588, | |||
20060111666, | |||
20060111674, | |||
20060129089, | |||
20060129122, | |||
20060167413, | |||
20060189933, | |||
20060253083, | |||
20070049865, | |||
20070129674, | |||
20070142776, | |||
20070161960, | |||
20070197976, | |||
20070239117, | |||
20080097337, | |||
20080120798, | |||
20080195052, | |||
20080195056, | |||
20080208125, | |||
20080208140, | |||
20080269692, | |||
20080300549, | |||
20090024076, | |||
20090024093, | |||
20090036870, | |||
20090157012, | |||
20090240195, | |||
20090240210, | |||
20090299328, | |||
20100080087, | |||
20100160869, | |||
20100160894, | |||
20110054414, | |||
20110146015, | |||
20110178469, | |||
20110178500, | |||
20110218502, | |||
20110257602, | |||
20120022499, | |||
20120107783, | |||
20120197209, | |||
20120233834, | |||
20120238961, | |||
20120255136, | |||
D322479, | Jun 02 1989 | TERUMO KABUSHIKI KAISHA, A CORP OF JAPAN | Holder for lancet |
D343897, | Dec 21 1990 | Glaxo Group Limited | Auto-injector for medicant |
D346219, | Nov 25 1991 | PHOENIX MEDICAL, INC | Erection pump |
D461555, | May 25 2000 | Sanofi-Synthelabo | Safety syringe |
D494270, | Feb 04 2003 | Covidien AG; TYCO HEALTHCARE GROUP AG | Electrosurgical pencil with multiple scallops |
D518175, | Oct 31 2003 | Cook Medical Technologies LLC | Handle for medical devices, and medical device assemblies using a handle |
D622374, | Sep 06 2006 | AbbVie Biotechnology Ltd | Automatic injection device |
D629509, | Sep 06 2006 | AbbVie Biotechnology Ltd | Automatic injection device |
D638935, | Jun 25 2010 | Abbott Cardiovascular Systems Inc. | Medical device handle |
D677380, | Jan 24 2011 | AbbVie Biotechnology Ltd | Automatic injection device |
DE19821933, | |||
DE2019296, | |||
DE60207576, | |||
EP68864, | |||
EP1334740, | |||
EP1364667, | |||
EP1523360, | |||
EP2067496, | |||
EP2085104, | |||
GB2243552, | |||
GB2388033, | |||
GB2424837, | |||
JP2001512038, | |||
JP2006507060, | |||
JP5014835, | |||
JP5161712, | |||
RU2004256, | |||
RU2131748, | |||
RU2169584, | |||
WO2005097238, | |||
WO2010055608, | |||
WO9855168, | |||
WO9940958, | |||
WO137908, | |||
WO162319, | |||
WO3039633, | |||
WO3077968, | |||
WO3097133, | |||
WO3099358, | |||
WO4000397, | |||
WO2004047892, | |||
WO2004060451, | |||
WO2004067068, | |||
WO2005002653, | |||
WO20050113039, | |||
WO2005046765, | |||
WO2005079889, | |||
WO2005090836, | |||
WO2005115508, | |||
WO2005115509, | |||
WO2005115510, | |||
WO2005115511, | |||
WO2005115512, | |||
WO2005115513, | |||
WO2005115516, | |||
WO2006000785, | |||
WO2006058061, | |||
WO2008005315, | |||
WO9313819, | |||
WO9409839, | |||
WO9413342, | |||
WO9426333, | |||
WO9922789, | |||
WO9922792, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jan 24 2012 | Abbvie Biotechnology Ltd. | (assignment on the face of the patent) | / | |||
Apr 30 2012 | LI, CHUAN | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
May 01 2012 | JULIAN, JOSEPH F | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
May 01 2012 | EIGER, AARON B | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
May 01 2012 | KURTH, MARK | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
May 02 2012 | KATZ, SABRINA | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
May 08 2012 | CALLIF, ADAM | Abbott Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028186 | /0847 | |
Sep 20 2012 | Abbott Laboratories | AbbVie Biotechnology Ltd | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 030947 | /0096 | |
May 31 2013 | Abbott Laboratories | AbbVie Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 034268 | /0986 | |
Oct 05 2013 | STANGO, JAMES C | AbbVie Biotechnology Ltd | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 031477 | /0382 |
Date | Maintenance Fee Events |
Jul 16 2019 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jul 13 2023 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Date | Maintenance Schedule |
Feb 23 2019 | 4 years fee payment window open |
Aug 23 2019 | 6 months grace period start (w surcharge) |
Feb 23 2020 | patent expiry (for year 4) |
Feb 23 2022 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 23 2023 | 8 years fee payment window open |
Aug 23 2023 | 6 months grace period start (w surcharge) |
Feb 23 2024 | patent expiry (for year 8) |
Feb 23 2026 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 23 2027 | 12 years fee payment window open |
Aug 23 2027 | 6 months grace period start (w surcharge) |
Feb 23 2028 | patent expiry (for year 12) |
Feb 23 2030 | 2 years to revive unintentionally abandoned end. (for year 12) |